AI Engines For more Details: Perplexity Kagi Labs You
Antidepressant Effects: Minaprine has been studied as an antidepressant medication. It is believed to exert its antidepressant effects by inhibiting the reuptake of serotonin and norepinephrine in the brain, thereby increasing the levels of these neurotransmitters. This mechanism is similar to that of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), which are commonly used antidepressants.
Neuroprotective Properties: Minaprine has also been investigated for its potential neuroprotective properties. It may help protect neurons from damage and degeneration, which could be beneficial in the treatment of neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease. However, further research is needed to fully understand minaprine's neuroprotective mechanisms and its potential clinical applications.
Enhancement of Cognitive Function: Some studies suggest that minaprine may have cognitive-enhancing effects, particularly in individuals with cognitive deficits associated with aging or neurological conditions. By modulating neurotransmitter levels and promoting neuronal health, minaprine may improve cognitive function and memory performance.
Treatment of Other Conditions: In addition to depression and neurodegenerative disorders, minaprine has been investigated for the treatment of other conditions, including schizophrenia, anxiety disorders, and attention deficit hyperactivity disorder (ADHD). However, its efficacy in these conditions has not been conclusively established, and more research is needed to determine its therapeutic potential.
Side Effects: Like any medication, minaprine may cause side effects in some individuals. Common side effects may include gastrointestinal disturbances, dizziness, headache, insomnia, and changes in appetite or weight. Serious side effects are rare but may include cardiac arrhythmias, allergic reactions, and serotonin syndrome (particularly when used in combination with other serotonergic medications). Patients should be monitored closely for adverse reactions while taking minaprine.
Drug Interactions: Minaprine may interact with other medications, particularly those that affect serotonin levels in the brain. Concurrent use of minaprine with monoamine oxidase inhibitors (MAOIs), SSRIs, SNRIs, tricyclic antidepressants, and other serotonergic agents should be avoided due to the risk of serotonin syndrome.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Lacticaseibacillus | genus | Decreases |
| 0 | 1 | Fusobacterium | genus | Decreases |
| 0 | 1 | Phocaeicola | genus | Decreases |
| 0 | 1 | Agathobacter | genus | Decreases |
| 0 | 1 | Bacteroides | genus | Decreases |
| 0 | 1 | Thomasclavelia | genus | Decreases |
| 0 | 1 | Clostridium | genus | Decreases |
| 0 | 1 | Mediterraneibacter | genus | Decreases |
| 0 | 1 | Lacrimispora | genus | Decreases |
| 0 | 1 | Escherichia | genus | Decreases |
| 0 | 1 | Clostridium perfringens A | no rank | Decreases |
| 0 | 1 | Clostridium perfringens B | no rank | Decreases |
| 0 | 1 | Clostridium perfringens C | no rank | Decreases |
| 0 | 1 | Clostridium perfringens CPE | no rank | Decreases |
| 0 | 1 | Clostridium perfringens D | no rank | Decreases |
| 0 | 1 | Clostridium perfringens E | no rank | Decreases |
| 0 | 1 | Escherichia coli O1:K1:H7 | no rank | Decreases |
| 0 | 1 | Escherichia coli O139:H1 | no rank | Decreases |
| 0 | 1 | Escherichia coli O141:H4 | no rank | Decreases |
| 0 | 1 | Escherichia coli O145:H34 | no rank | Decreases |
| 0 | 1 | Escherichia coli O15:H12 | no rank | Decreases |
| 0 | 1 | Escherichia coli O155:H21 | no rank | Decreases |
| 0 | 1 | Escherichia coli O158:H23 | no rank | Decreases |
| 0 | 1 | Escherichia coli O16:H48 | no rank | Decreases |
| 0 | 1 | Escherichia coli O170:H18 | no rank | Decreases |
| 0 | 1 | Escherichia coli O18ac:H14 | no rank | Decreases |
| 0 | 1 | Escherichia coli O19:H7 | no rank | Decreases |
| 0 | 1 | Escherichia coli O2:K1:H4 | no rank | Decreases |
| 0 | 1 | Escherichia coli O2:K1:H5 | no rank | Decreases |
| 0 | 1 | Escherichia coli O2:K1:H7 | no rank | Decreases |
| 0 | 1 | Escherichia coli O20:H12 | no rank | Decreases |
| 0 | 1 | Escherichia coli O25:H16 | no rank | Decreases |
| 0 | 1 | Escherichia coli O55:H7 | no rank | Decreases |
| 0 | 1 | Escherichia coli O68:H12 | no rank | Decreases |
| 0 | 1 | Escherichia coli O7:H15 | no rank | Decreases |
| 0 | 1 | Escherichia coli O78:H51 | no rank | Decreases |
| 0 | 1 | Escherichia coli O80:H26 | no rank | Decreases |
| 0 | 1 | Escherichia coli O84:H7 | no rank | Decreases |
| 0 | 1 | Escherichia coli O85:H1 | no rank | Decreases |
| 0 | 1 | Escherichia coli O103 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O111 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O119 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O121 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O145 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O155 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O157 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O177 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O26 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O3 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O43 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O5 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O78 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O86 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O91 | serogroup | Decreases |
| 0 | 1 | Escherichia coli H20 | serotype | Decreases |
| 0 | 1 | Escherichia coli O1:H42 | serotype | Decreases |
| 0 | 1 | Escherichia coli O1:HNT | serotype | Decreases |
| 0 | 1 | Escherichia coli O10:H32 | serotype | Decreases |
| 0 | 1 | Escherichia coli O10:K5(L):H4 | serotype | Decreases |
| 0 | 1 | Escherichia coli O100:H21 | serotype | Decreases |
| 0 | 1 | Escherichia coli O103:H11 | serotype | Decreases |
| 0 | 1 | Escherichia coli O103:H2 | serotype | Decreases |
| 0 | 1 | Escherichia coli O103:H25 | serotype | Decreases |
| 0 | 1 | Escherichia coli O104:H21 | serotype | Decreases |
| 0 | 1 | Escherichia coli O104:H4 | serotype | Decreases |
| 0 | 1 | Escherichia coli O111:H- | serotype | Decreases |
| 0 | 1 | Escherichia coli O111:H11 | serotype | Decreases |
| 0 | 1 | Escherichia coli O111:H8 | serotype | Decreases |
| 0 | 1 | Escherichia coli O111:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O112ab:H8 | serotype | Decreases |
| 0 | 1 | Escherichia coli O112ac:H19 | serotype | Decreases |
| 0 | 1 | Escherichia coli O113:H21 | serotype | Decreases |
| 0 | 1 | Escherichia coli O114:H49 | serotype | Decreases |
| 0 | 1 | Escherichia coli O118:H16 | serotype | Decreases |
| 0 | 1 | Escherichia coli O121:H19 | serotype | Decreases |
| 0 | 1 | Escherichia coli O121:H7 | serotype | Decreases |
| 0 | 1 | Escherichia coli O123:H11 | serotype | Decreases |
| 0 | 1 | Escherichia coli O125ac:K+:H10 | serotype | Decreases |
| 0 | 1 | Escherichia coli O126:H45 | serotype | Decreases |
| 0 | 1 | Escherichia coli O127:H27 | serotype | Decreases |
| 0 | 1 | Escherichia coli O127:H6 | serotype | Decreases |
| 0 | 1 | Escherichia coli O128:H2 | serotype | Decreases |
| 0 | 1 | Escherichia coli O128ac:H12 | serotype | Decreases |
| 0 | 1 | Escherichia coli O139:H28 | serotype | Decreases |
| 0 | 1 | Escherichia coli O145:H25 | serotype | Decreases |
| 0 | 1 | Escherichia coli O145:H28 | serotype | Decreases |
| 0 | 1 | Escherichia coli O145:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O146:H21 | serotype | Decreases |
| 0 | 1 | Escherichia coli O15:H18 | serotype | Decreases |
| 0 | 1 | Escherichia coli O150:H6 | serotype | Decreases |
| 0 | 1 | Escherichia coli O152:H23 | serotype | Decreases |
| 0 | 1 | Escherichia coli O153:H2 | serotype | Decreases |
| 0 | 1 | Escherichia coli O156:H25 | serotype | Decreases |
| 0 | 1 | Escherichia coli O157:H- | serotype | Decreases |
| 0 | 1 | Escherichia coli O157:H43 | serotype | Decreases |
| 0 | 1 | Escherichia coli O157:H7 | serotype | Decreases |
| 0 | 1 | Escherichia coli O157:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O16:H6 | serotype | Decreases |
| 0 | 1 | Escherichia coli O165:H25 | serotype | Decreases |
| 0 | 1 | Escherichia coli O167:H26 | serotype | Decreases |
| 0 | 1 | Escherichia coli O174:H2 | serotype | Decreases |
| 0 | 1 | Escherichia coli O174:H21 | serotype | Decreases |
| 0 | 1 | Escherichia coli O174:H8 | serotype | Decreases |
| 0 | 1 | Escherichia coli O176:H45 | serotype | Decreases |
| 0 | 1 | Escherichia coli O177:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O2:H6 | serotype | Decreases |
| 0 | 1 | Escherichia coli O2:K2:H1 | serotype | Decreases |
| 0 | 1 | Escherichia coli O25:H1 | serotype | Decreases |
| 0 | 1 | Escherichia coli O25:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O26:H1 | serotype | Decreases |
| 0 | 1 | Escherichia coli O26:H11 | serotype | Decreases |
| 0 | 1 | Escherichia coli O28ac:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O29:H4 | serotype | Decreases |
| 0 | 1 | Escherichia coli O32:H37 | serotype | Decreases |
| 0 | 1 | Escherichia coli O39:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O44:H18 | serotype | Decreases |
| 0 | 1 | Escherichia coli O45:H2 | serotype | Decreases |
| 0 | 1 | Escherichia coli O6:H16 | serotype | Decreases |
| 0 | 1 | Escherichia coli O6:H16:CFA/II | serotype | Decreases |
| 0 | 1 | Escherichia coli O6:K2:H1 | serotype | Decreases |
| 0 | 1 | Escherichia coli O69:H11 | serotype | Decreases |
| 0 | 1 | Escherichia coli O7:H4 | serotype | Decreases |
| 0 | 1 | Escherichia coli O7:K1 | serotype | Decreases |
| 0 | 1 | Escherichia coli O78:H12 | serotype | Decreases |
| 0 | 1 | Escherichia coli O78:H4 | serotype | Decreases |
| 0 | 1 | Escherichia coli O79:H7 | serotype | Decreases |
| 0 | 1 | Escherichia coli O8:H8 | serotype | Decreases |
| 0 | 1 | Escherichia coli O81:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O83:H1 | serotype | Decreases |
| 0 | 1 | Escherichia coli O86:H34 | serotype | Decreases |
| 0 | 1 | Escherichia coli O89m:H10 | serotype | Decreases |
| 0 | 1 | Escherichia coli O89m:H9 | serotype | Decreases |
| 0 | 1 | Escherichia coli O9:H10 | serotype | Decreases |
| 0 | 1 | Escherichia coli O91:H14 | serotype | Decreases |
| 0 | 1 | Escherichia coli O91:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O99:H6 | serotype | Decreases |
| 0 | 1 | Escherichia coli ONT:H33 | serotype | Decreases |
| 1 | 0 | Lacticaseibacillus paracasei | species | Decreases |
| 1 | 0 | Fusobacterium nucleatum | species | Decreases |
| 1 | 0 | Phocaeicola vulgatus | species | Decreases |
| 1 | 0 | Bacteroides fragilis | species | Decreases |
| 1 | 0 | Agathobacter rectalis | species | Decreases |
| 1 | 0 | Thomasclavelia ramosa | species | Decreases |
| 1 | 0 | Clostridium perfringens | species | Decreases |
| 1 | 0 | [Ruminococcus] torques | species | Decreases |
| 1 | 0 | Lacrimispora saccharolytica | species | Decreases |
| 1 | 0 | Bacteroides thetaiotaomicron | species | Decreases |
| 1 | 0 | Escherichia coli | species | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. paracasei | subspecies | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. tolerans | subspecies | Decreases |
| 0 | 1 | Fusobacterium nucleatum subsp. nucleatum | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0 | 0 | |
| ADHD | 0.4 | 0.4 | |
| Allergic Rhinitis (Hay Fever) | 0.1 | 0 | 0 |
| Allergies | 0.5 | 0.4 | 0.25 |
| Allergy to milk products | 0.1 | 0.1 | 0 |
| Alzheimer's disease | 1.2 | 0.5 | 1.4 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.2 | 0 | 0 |
| Ankylosing spondylitis | 0.1 | 0.3 | -2 |
| Anorexia Nervosa | 0 | 0.3 | 0 |
| Antiphospholipid syndrome (APS) | 0 | 0 | |
| Asthma | 0.6 | 0.1 | 5 |
| Atherosclerosis | 0.6 | 0 | 0 |
| Atrial fibrillation | 0.3 | 0.2 | 0.5 |
| Autism | 1.1 | 1.2 | -0.09 |
| Autoimmune Disease | 0 | 0 | 0 |
| Barrett esophagus cancer | 0.3 | 0.3 | |
| benign prostatic hyperplasia | 0 | 0.1 | 0 |
| Biofilm | 0.6 | 0.6 | |
| Bipolar Disorder | 0.1 | 0.1 | |
| Brain Trauma | 0.1 | -0.1 | |
| Breast Cancer | 0.6 | 0.6 | |
| Cancer (General) | 0.3 | 0.7 | -1.33 |
| Carcinoma | 0.9 | 0.1 | 8 |
| Celiac Disease | 0.7 | 0.1 | 6 |
| Cerebral Palsy | 0.1 | 0.1 | 0 |
| Chronic Fatigue Syndrome | 0.8 | 0.7 | 0.14 |
| Chronic Kidney Disease | 0.1 | 0.2 | -1 |
| Chronic Lyme | 0.1 | -0.1 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.3 | 0.3 | 0 |
| Chronic Urticaria (Hives) | 0 | 0.2 | 0 |
| Coagulation / Micro clot triggering bacteria | 0 | 0 | |
| Cognitive Function | 0.1 | 0 | 0 |
| Colorectal Cancer | 1.9 | 0.4 | 3.75 |
| Constipation | 0.5 | 0.5 | |
| Coronary artery disease | 0.1 | 0.4 | -3 |
| COVID-19 | 1 | 0.8 | 0.25 |
| Crohn's Disease | 1.6 | 0.7 | 1.29 |
| Cushing's Syndrome (hypercortisolism) | 0.5 | -0.5 | |
| cystic fibrosis | 0 | 0.1 | 0 |
| d-lactic acidosis (one form of brain fog) | 0 | 0 | |
| deep vein thrombosis | 0.8 | 0.1 | 7 |
| Denture Wearers Oral Shifts | 0.6 | 0.6 | |
| Depression | 1.7 | 0.9 | 0.89 |
| Eczema | 0.3 | 0.2 | 0.5 |
| Endometriosis | 0.1 | 0 | 0 |
| Eosinophilic Esophagitis | 0.3 | 0.3 | |
| Epilepsy | 0.6 | 0.1 | 5 |
| erectile dysfunction | 0.4 | 0.4 | |
| Fibromyalgia | 0.1 | 0.1 | 0 |
| Functional constipation / chronic idiopathic constipation | 0.8 | 0.3 | 1.67 |
| gallstone disease (gsd) | 0.2 | 0.3 | -0.5 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.5 | 1.5 | |
| Generalized anxiety disorder | 0.4 | 0.1 | 3 |
| giant cell arteritis | 0 | 0 | |
| Gout | 0.1 | 0 | 0 |
| Graves' disease | 0.1 | 0.1 | 0 |
| Gulf War Syndrome | 0 | 0.2 | 0 |
| Halitosis | 0.9 | 0.9 | |
| Hashimoto's thyroiditis | 0.6 | 0.1 | 5 |
| Heart Failure | 0.7 | 0.1 | 6 |
| hemorrhagic stroke | 0.3 | 0.3 | |
| Hidradenitis Suppurativa | 0.3 | 0.3 | |
| High Histamine/low DAO | 0.1 | 0.1 | |
| hypercholesterolemia (High Cholesterol) | 0 | 0 | |
| hyperglycemia | 0 | 0.1 | 0 |
| hypertension (High Blood Pressure | 0.1 | 0.3 | -2 |
| Hypoxia | 0.1 | 0.1 | |
| IgA nephropathy (IgAN) | 0.3 | 0 | 0 |
| Inflammatory Bowel Disease | 1.8 | 0.8 | 1.25 |
| Insomnia | 0.1 | 0.1 | 0 |
| Intelligence | 0.1 | 0.1 | |
| Intracranial aneurysms | 0.3 | 0.3 | |
| Irritable Bowel Syndrome | 0.9 | 0.6 | 0.5 |
| ischemic stroke | 0.1 | 0.1 | 0 |
| Liver Cirrhosis | 0.7 | 0.4 | 0.75 |
| Long COVID | 1 | 0.4 | 1.5 |
| Lung Cancer | 0 | 0 | |
| Lymphoma | 0 | 0 | |
| Mast Cell Issues / mastitis | 0.6 | 0.6 | |
| ME/CFS with IBS | 0 | 0.1 | 0 |
| ME/CFS without IBS | 0 | 0.1 | 0 |
| Metabolic Syndrome | 0.6 | 1 | -0.67 |
| Mood Disorders | 1.2 | 0.9 | 0.33 |
| Multiple Sclerosis | 0.8 | 0.5 | 0.6 |
| myasthenia gravis | 0 | 0 | 0 |
| neuropathic pain | 0.1 | -0.1 | |
| Neuropathy (all types) | 0 | 0 | |
| neuropsychiatric disorders (PANDAS, PANS) | 0 | 0 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.5 | 0.2 | 1.5 |
| NonCeliac Gluten Sensitivity | 0.1 | 0.1 | 0 |
| Obesity | 0.4 | 1.8 | -3.5 |
| obsessive-compulsive disorder | 0.7 | 0.2 | 2.5 |
| Osteoarthritis | 0.2 | 0.1 | 1 |
| Osteoporosis | 0.1 | 0.1 | 0 |
| pancreatic cancer | 0.6 | 0.6 | |
| Parkinson's Disease | 0.3 | 0.9 | -2 |
| Polycystic ovary syndrome | 1 | 0.1 | 9 |
| Postural orthostatic tachycardia syndrome | 0 | 0 | |
| primary biliary cholangitis | 0.3 | -0.3 | |
| Primary sclerosing cholangitis | 0.4 | 0 | 0 |
| Psoriasis | 0.2 | 0.2 | 0 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.6 | 0.7 | -0.17 |
| Rosacea | 0 | 0 | 0 |
| Schizophrenia | 0.4 | 0.1 | 3 |
| scoliosis | 0 | 0 | |
| Sjögren syndrome | 0 | 0.1 | 0 |
| Sleep Apnea | 0.3 | 0.1 | 2 |
| Slow gastric motility / Gastroparesis | 0.1 | 0.1 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.4 | 0.4 | |
| Stress / posttraumatic stress disorder | 0.4 | 0.1 | 3 |
| Systemic Lupus Erythematosus | 0.6 | 0 | 0 |
| Tic Disorder | 0.5 | 0.5 | |
| Tourette syndrome | 0.1 | -0.1 | |
| Type 1 Diabetes | 0.8 | 0.6 | 0.33 |
| Type 2 Diabetes | 1.3 | 1.5 | -0.15 |
| Ulcerative colitis | 2 | 0.8 | 1.5 |
| Unhealthy Ageing | 1.6 | 0.1 | 15 |
| Vitiligo | 0.3 | 0 | 0 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
